Page last updated: 2024-10-21

3-methylcholanthrene and Myasthenia Gravis

3-methylcholanthrene has been researched along with Myasthenia Gravis in 1 studies

Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.
3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Watanabe, H1

Other Studies

1 other study available for 3-methylcholanthrene and Myasthenia Gravis

ArticleYear
A pathological study of thymomas.
    Acta pathologica japonica, 1966, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Female; Humans; Infant; Leukemia; Male; M

1966